Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Gene dosage of the apolipoprotein E (APOE) epsilon 4 allele is a major risk factor for familial Alzheimer disease (AD) of late onset (after age 60). Here we studied a large series of 115 AD case subjects and 243 controls as well as 150 affected and 197 unaffected members of 66 AD families. Our data demonstrate a protective effect of the epsilon 2 allele, in addition to the dose effect of the epsilon 4 allele in sporadic AD. Although a substantial proportion (65%) of AD is attributable to the presence of epsilon 4 alleles, risk of AD is lowest in subjects with the epsilon 2/epsilon 3 genotype, with an additional 23% of AD attributable to the absence of an epsilon 2 allele. The opposite actions of the epsilon 2 and epsilon 4 alleles further support the direct involvement of APOE in the pathogenesis of AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“APOE, the major susceptibility gene for late-onset AD, has three common alleles (APOE2, 3, and 4).”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [10]
In the citing paper
“Compared to the most common APOE3/3 genotype, which is considered neutral with regard to AD risk, APOE2 is associated with a lower AD risk and older age at dementia onset, and each additional copy of APOE4 is associated with a higher risk and younger age at onset.10”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [10]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [2]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [2]
38 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Self-citationGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationApolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationDiagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationStrittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citation
Research works printed but not linked: 2
- Cornoni-Huntley, J., Blazer, D.G., Service, C. & Farmer, M.E. in Established population for epidemiologic studies of the elderly. Volume II (eds Cornoni-Huntley, J. et al.) 1–7 (NIH publication 90–495, Bethesda, 1990).
- Rothman, K.J. Modern Epidemiology. 38–39, 76 (Little, Brown & Company, Boston, 1986).
Cited by
Items 901–1,000 of 1,029
Dorey, E., Bamji-Mirza, M., Najem, D., Li, Y., Liu, H., Callaghan, D., Walker, D., Lue, L.-F., Stanimirovic, D., & Zhang, W. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160133 · Cited by 27
“The 2 allele is associated with neuroprotection for AD [3, 4], while the 4 allele is a very strong risk factor for AD.”
Genome-wide significant risk factors on chromosome 19 and the APOE locus
Moreno–Grau, S., Initiative, A. D. N., Hernández, I., Heilmann‐Heimbach, S., Ruiz, S., Rosende‐Roca, M., Mauleón, A., Vargas, L., Rodríguez‐Gómez, O., Alegret, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25083 · Cited by 31
“While the Ɛ2 allele of APOE is determined by the minor allele of rs7412:C>T and is protective for LOAD [3], the minor allele of rs429358:C>T defines the Ɛ4 allele, which increases the risk of LOAD [2] by up to four-fold.”
BackgroundA short perspective on the long road to effective treatments for Alzheimer's disease
Reynolds, D. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14581 · Cited by 30
“Several genome wide association studies involving hundreds of thousands of subjects have now identified approximately 30 risk alleles (Guerreiro & Hardy, 2014; Zhu, Tan, Tan, & Yu, 2017) and two protective variants (ApoEε2 and PLCγ2; Corder et al., 1994; Sims et al., 2017).”
BackgroundAlzheimer'S Disease: Advances In Genetics, Molecular And Cellular Biology
Sisodia, S. S., & Tanzi, R. E. (2007) · Cited by 30
Apolipoprotein E in schizophrenia: A French association study and meta‐analysis
Schürhoff, F., Krebs, M., Szöke, A., Loze, J.-Y., Goldberger, C., Quignon, V., Tignol, J., Rouillon, F., Laplanche, J., & Leboyer, M. (2003) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20007 · Cited by 27
“Interestingly, several investigations have provided evidence that the ApoE e2 allele has a protective effect against dementing illnesses such as late-onset AD [Corder et al., 1994] and Creutzfeldt-Jakob disease [Amouyel et al., 1994], independent of the over-representation of the ApoE e4 allele.”
BackgroundSpencer, K. L., Hauser, M. A., Olson, L. M., Schnetz‐Boutaud, N. C., Scott, W. K., Schmidt, S., Gallins, P. J., Agarwal, A., Postel, E. A., Pericak‐Vance, M. A., et al. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.06-1427 · Cited by 30
“This test has been used to show that the frequency of the APOE epsilon 2 allele is reduced in Alzheimer’s disease, even after allowing for the increased frequency of the risk APOE epsilon 4 allele in cases of Alzheimer’s.38 A logistic regression model considering P1, P2, and risk haplotypes with the neutral haplotype…”
BackgroundSelf-citationAPOE ε4 and the cognitive genetics of multiple sclerosis
Ghaffar, O., Reis, M., Pennell, N., O'Connor, P., & Feinstein, A. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e074a7 · Cited by 27
Protective effect of the apo ɛ 2 allele in major depressive disorder in Taiwanese
Fan, P. ‐., Chen, C. ‐., Kao, W. ‐., Shu, B. ‐., & Lung, F. ‐. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2005.00686.x · Cited by 27
“The apo e4 allele is widely accepted to be a risk factor for late-onset AD, in a dose-dependent manner (18), while the presence of the apo e2 allele might be a protective factor against AD (19, 20).”
BackgroundOraguzie, N. C., Wilcox, P. L., Rikkerink, E. H. A., & de Silva, H. N. (2007) · Springer eBooks · doi:10.1007/978-0-387-36011-9_2 · Cited by 37
Age-related congophilic inclusions in the brains of apolipoprotein E-deficient mice
Robertson, T. A., Dutton, N., Martins, R. N., Roses, A. D., Kakulas, B. A., & Papadimitriou, J. M. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00284-4 · Cited by 33
Self-citationGene identification in Alzheimer’s disease
Saunders, A. M. (2001) · Pharmacogenomics · doi:10.1517/14622416.2.3.239 · Cited by 34
Self-citationBa, H. C., Roberts, C. T., Greenberg, S. M., Rebeck, G. W., Bs, R. C., Wallace, R. B., Jacob, H. J., & Hyman, B. T. (1996) · Annals of Neurology · doi:10.1002/ana.410390617 · Cited by 28
Amyloid plaque-associated oxidative degradation of uniformly radiolabeled arachidonic acid
Furman, R., Murray, I. V. J., Schall, H. E., Liu, Q., Ghiwot, Y., & Axelsen, P. H. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00316 · Cited by 26
Role of Apolipoprotein E in Alzheimer’s Disease
Zannis, V. I., Zanni, E. E., Makrides, S. C., Kardassis, D., & Aleshkov, S. B. (1998) · Springer eBooks · doi:10.1007/978-1-4899-0133-0_13 · Cited by 27
Olofsson, J., Larsson, M. U., Roa, C., Wilson, D. A., & Laukka, E. J. (2019) · Behavior Genetics · doi:10.1007/s10519-019-09980-9 · Cited by 30
Fulton‐Howard, B., Goate, A., Adelson, R. P., Koppel, J. L., Gordon, M. L., Barzilai, N., Atzmon, G., Davies, P., & Freudenberg‐Hua, Y. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.09.014 · Cited by 29
Mhatre‐Winters, I., Eid, A., Han, Y., Tieu, K., & Richardson, J. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179829 · Cited by 26
“In contrast, APOE2, present in 9% of the general population and 5% of all AD cases, has been documented to be protective for AD [20].”
BackgroundPossible Association of APOE Genotype with Working Memory in Young Adults
Sinclair, L. I., Button, K. S., Munafo, M. R., Day, I. N. M., & Lewis, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135894 · Cited by 29
“Previous studies have reported that ε2 possession is associated with better cognitive performance in old age, in contrast to our findings.[39, 40] Interestingly, neuropathological studies have suggested that this protection declines in old age, particularly after the age of 80.”
ResultApolipoprotein E ε4 and Later-Life Decline in Cognitive Function and Grip Strength
Batterham, P. J., Bunce, D. J., Cherbuin, N., & Christensen, H. M. (2013) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.01.035 · Cited by 32
Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer
Sasaki (1994) · Oncology Reports · doi:10.3892/or_00000119 · Cited by 26
“Efforts are under way to identify the single nucleotide polymorphisms (SNPs) or mutations in lung cancers and, in clinical data, to establish correlations with disease susceptibility, progression and response to therapeutic regimens (2).”
Bunce, D. J., Anstey, K. J., Cherbuin, N., Gautam, P., Sachdev, P. S., & Easteal, S. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-112126 · Cited by 27
“Given evidence that possession of the ε4 allele is a risk factor for AD [5] while the ε2 allele offers protection [6], the present finds are of some importance.”
BackgroundMcMillan, C. T., Lee, E. B., Jefferson‐George, K., Naj, A. C., Deerlin, V. M. V., Trojanowski, J. Q., & Wolk, D. A. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.581 · Cited by 29
“These findings are also consistent with prior claims that APOEe2 may provide a neuroprotective benefit against the risk of Ab pathology.(20) While we did not observe a significant association between APOEe2 and NFT severity in individuals with Ab pathology (i.”
ResultNeuro-Immuno-Gene- and Genome-Editing-Therapy for Alzheimer’s Disease: Are We There Yet?
Raikwar, S. P., Thangavel, R., Dubova, I., Ahmed, M. E., Selvakumar, G. P., Kempuraj, D., Zaheer, S. A., Iyer, S. S., & Zaheer, A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180422 · Cited by 32
St�ber, G., Hebebrand, J., Cichon, S., Br�ss, M., B�nisch, H., Lehmkuhl, G., Poustka, F., Schmidt, M., Remschmidt, H., Propping, P., et al. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19990416)88:2<158::aid-ajmg12>3.0.co;2-w · Cited by 47
Self-citationPiccardi, M., Congiu, D., Squassina, A., Manconi, F., Putzu, P. F., Mereu, R. M., Chillotti, C., & Zompo, M. D. (2007) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30548 · Cited by 28
“[Poirier et al., 1993; Strittmatter et al., 1993; Corder et al., 1994; Talbot et al., 1994].”
BackgroundNunomura, A., Chiba, S., Eto, M., Saito, M., Makino, I., & Miyagishi, T. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12415-0 · Cited by 28
Emotional Responses to APO E Genotype Disclosure for Alzheimer Disease
Romero, L. J., Garry, P. J., Schuyler, M. R., Bennahum, D. A., Qualls, C., Ballinger, L., Kelly, V., Schmitt, C. L., SKIPPER, B. J., Ortiz, I. E., et al. (2005) · Journal of Genetic Counseling · doi:10.1007/s10897-005-4063-1 · Cited by 26
“For our study, we considered the E2/ E4 genotype not to be at increased risk using the results of Corder et al. (1994) for reference.”
BackgroundMethodBowman, B. H., Jansen, L., Yang, F., Adrian, G. S., Zhao, M., Atherton, S. S., Buchanan, J. M., Greene, R., Walter, C., & Herbert, D. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.26.12115 · Cited by 26
Apolipoprotein E Genotype: Utility in Clinical Practice in Alzheimer's Disease
Roses, A. D., Bryan, J., & Bryan, K. (1996) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1996.tb04077.x · Cited by 25
Self-citationGünaydin, C., Sondhi, D., Kaminsky, S. M., Lephart, H. C., Leopold, P. L., Hackett, N. R., Khanna, R., & Crystal, R. G. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.003 · Cited by 26
White Matter Alterations in Cognitively Normal apoE ɛ2 Carriers: Insight into Alzheimer Resistance?
Chiang, G. C., Zhan, W., Schuff, N., & Weiner, M. W. (2012) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2984 · Cited by 25
“The finding of higher FA in the posterior cingulate white matter and corpus callosum of apoE 2 carriers, as evidenced by our ROI and whole-brain approaches, mirrors the pattern reported in prior literature comparing patients with AD and healthy individuals.7,8 The posterior cingulate is an integral component of the ep…”
BackgroundInfluentialAdditive genetic effect of APOE and BDNF on hippocampus activity
Kauppi, K., Nilsson, L., Persson, J., & Nyberg, L. H. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.11.049 · Cited by 31
“…(N = 2), ε2/ε4 (N = 10) and ε4/ε4 (N = 2) were excluded because of difficulty to interpret results from those smaller groups as the ε2 allele is thought to be protective, and a dose-dependent role of the APOE ε4 allele has been shown (Corder et al., 1994; Farrer et al., 1997; Lind et al., 2006).”
Sapkota, S., Vergote, D., Westaway, D. A., Jhamandas, J. H., & Dixon, R. A. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.020 · Cited by 27
DiBattista, A. M., Dumanis, S. B., Song, J. M., Bu, G., Weeber, E. J., Rebeck, G. W., & Hoe, H.-S. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.01.015 · Cited by 29
“Moreover, the gene encoding for the ligand of this receptor, APOE, is the strongest known genetic risk factor for Alzheimer’s disease [7].”
BackgroundNew molecular approaches to Alzheimer's disease
Resta, C. D., & Ferrari, M. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.04.010 · Cited by 30
Ingala, S., Mazzai, L., Sudre, C. H., Salvadó, G., Brugulat-Serrat, A., Wottschel, V., Falcon, C., Operto, G., Tijms, B., Gispert, J. D., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.06.015 · Cited by 25
“Although some reports conclude that APOE-ε2 is protective against AD development due to a reduced accumulation of amyloid deposition (Benjamin et al., 1994; Corder et al., 1994; Groot et al., 2018; Grothe et al., 2017; Rebeck et al., 2002), others indicated an increased prevalence of CAA-related cerebral hemorrhages i…”
ResultLozupone, M., Imbimbo, B. P., Balducci, C., Vecchio, F. L., Bisceglia, P., Latino, R. R., Leone, M. A., Dibello, V., Solfrizzi, V., Greco, A., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12728 · Cited by 30
Arginine-based PNA microarrays for APOE genotyping
Calabretta, A., Tedeschi, T., Cola, G. D., Corradini, R., Sforza, S., & Marchelli, R. (2009) · Molecular BioSystems · doi:10.1039/b909912n · Cited by 26
Dental Status Is Unrelated to Risk of Dementia: A 20‐Year Prospective Study
Hansson, P., Sörman, D. E., Bergdahl, J., Bergdahl, M., Nyberg, L. H., Adolfsson, R., & Nilsson, L. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12814 · Cited by 25
Bosco, P., Guéant‐Rodriguez, R., Anello, G., Spada, R. S., Romano, A. G., Caraci, F., Ferri, R., & Guéant, J. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.06.056 · Cited by 29
Chao, L. L., Reeb, R., Esparza, I. L., & Abadjian, L. R. (2016) · NeuroToxicology · doi:10.1016/j.neuro.2016.02.009 · Cited by 28
“Because the 2/4 combined allele has been associated with a lower risk of AD (Corder et al., 1994), these subjects were excluded from the APOE e4-positive group.”
Yamauchi (2000) · doi:10.1002/1097-4547(20001115)62:4
The Golgi apparatus and the pathogenesis of Alzheimer's disease.
Canto, M. C. D. (1996) · Europe PMC (PubMed Central) · Cited by 28
Differential Diagnosis and Early Detection of Dementia
Small, G. W. (1998) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-199821001-00004 · Cited by 31
Self-citationMolecular Genetics of Alzheimer's Disease
Verdile, G., & Martin, R. (2008) · Nucleic acids and molecular biology · doi:10.1007/978-3-540-85383-1_8 · Cited by 26
“The APOE ε2 allele, on the other hand, is associated with a delayed age of onset for AD (Chartier-Harlin et al. 1994; Corder et al. 1994; Talbot et al. 1994; West et al. 1994; Roses et al. 1995), even in the presence of the APP – V717I mutation.”
BackgroundFamilial and Population‐Based Studies of Apolipoprotein E and Alzheimer's Diseasea
MULLAN, M., SCIBELLI, P., DUARA, R., FALLIN, D., GOLD, M., SCHINKA, J., HOYNE, J., OSBORNE, A., SEVUSH, S., & CRAWFORD, F. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb32594.x · Cited by 25
Zubenko, G. S. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000713 · Cited by 25
“The APOE e2 allele may confer an independent protective effect against the development of late onset AD”
BackgroundCerebral amyloid angiopathy and apolipoprotein E: Bad news for the good allele?
Greenberg, S. M., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410604 · Cited by 30
Budny, V., Ruminot, I., Wybitul, M., Treyer, V., Barros, L. F., & Tackenberg, C. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03550-w · Cited by 25
“In contrast, APOE2 is known to lower the AD risk [13 – 15].”
Stimulating myelin restoration with BDNF: a promising therapeutic approach for Alzheimer's disease
Zota, I., Chanoumidou, K., Gravanis, A., & Charalampopoulos, I. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1422130 · Cited by 26
Kõks, S., Pfaff, A. L., Bubb, V. J., & Quinn, J. P. (2021) · Genes · doi:10.3390/genes12030423 · Cited by 23
“The effect of e4 is dosage-dependent on the risk of AD and at the same time e2 variant of ApoE exhibits protective effect for late onset AD [2].”
BackgroundAlternative Targets to Fight Alzheimer’s Disease: Focus on Astrocytes
Valenza, M., Facchinetti, R., Menegoni, G., Steardo, L., & Scuderi, C. (2021) · Biomolecules · doi:10.3390/biom11040600 · Cited by 26
“Homozygous carriers for the isoform ε4 have about a 12-fold higher risk to develop sporadic AD, while carriers of the less frequent ε2 isoform show a low risk for AD [70,71].”
BackgroundC. elegans as an Animal Model to Study the Intersection of DNA Repair, Aging and Neurodegeneration
Naranjo-Galindo, F. J., Ai, R., Fang, E. F., Nilsen, H. L., & SenGupta, T. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.916118 · Cited by 31
Genetic Polymorphisms in Sepsis- and Cardiopulmonary Bypass-Associated Acute Kidney Injury
Haase‐Fielitz, A., Haase, M., Bellomo, R., & Dragun, D. (2007) · KARGER eBooks · doi:10.1159/000102072 · Cited by 25
Apolipoprotein E Polymorphism and Age at Onset of Alzheimer’s Disease in a Quadriethnic Sample
Kwon, O. D., Khaleeq, A., Chan, W., Pavlik, V., & Doody, R. S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000322368 · Cited by 25
Will testing for apolipoprotein E assist in tailoring dementia risk reduction? A review
Low, L., Yap, M., & Brodaty, H. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.08.007 · Cited by 26
“435 Apolipoprotein E (ApoE) is the only gene to be consistently shown to increase the risk for sporadic Alzheimer’s disease (AD) (Corder et al., 1994; Farrer et al., 1997).”
How understudied populations have contributed to our understanding of Alzheimer’s disease genetics
Dehghani, N., Brás, J., & Guerreiro, R. J. (2021) · Brain · doi:10.1093/brain/awab028 · Cited by 25
Chen, L., Baum, L., Ng, H., Chan, L. Y. S., & Pang, C. (1999) · Human Pathology · doi:10.1016/s0046-8177(99)90034-5 · Cited by 27
Familial Occurrence of Dementia and Parkinsonism
Kurz, M. W., Schlitter, A. M., Larsen, J. P., Ballard, C. G., & Aarsland, D. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000095159 · Cited by 27
“Primarily, the APOe4 allele is known to be associated with familial and sporadic late-onset AD [ ,”
BackgroundApolipoprotein E Genotype in Sporadic Early- and Late-Onset Alzheimer’s Disease
Masullo, C., Daniele, A., Seripa, D., Filippini, V., Gravina, C., Carbone, G., Gainotti, G., & Fazio, V. M. (1998) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017034 · Cited by 24
Lack of Association between the Apolipoprotein E Genotype and Depression in Alzheimer's Disease
Liu, C., Hong, C., Liu, T., Lin, K.-N., Wang, P.-N., Chi, C., Chuang, Y.-Y., & Liu, H.-C. (2002) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198870201500105 · Cited by 25
No implication of apolipoprotein E polymorphism in Italian schizophrenic patients
Sorbi, S., Nacmias, B., Tedde, A., Latorraca, S., Forleo, P., Guarnieri, B., Petruzzi, C., Daneluzzo, E., Ortenzi, L., Piacentini, S., et al. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00144-x · Cited by 26
There Is a Pathologic Relationship Between ApoE- 4 and Alzheimer's Disease
Corder, E. H., Saunders, A. M., Pericak‐Vance, M. A., & Roses, A. D. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540310012003 · Cited by 24
Self-citationMicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease
Yoon, H., Flores, L. F., & Kim, J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.04.020 · Cited by 29
“APOE4 allele increases the risk of developing AD, whereas APOE2 allele is protective [70, 71].”
BackgroundProtective ApoE variants support neuronal function by effluxing oxidized phospholipids
Ralhan, I., Do, A. D., Bae, J.-Y., Feringa, F. M., Cai, W., Chang, J., Chik, K., Lee, N. Y. J., Gerry, C. J., van der Kant, R., et al. (2026) · Neuron · doi:10.1016/j.neuron.2025.10.040 · Cited by 23
Woody, S. K., Zhou, H., Ibrahimi, S., Dong, Y., & Zhao, L. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160307 · Cited by 23
“ApoE2 is relatively rare, with only 5% incidence, and is considered to be a neuroprotective variant [15].”
BackgroundKara, E., Marks, J. D., Fan, Z., Klickstein, J. A., Roe, A. D., Krogh, K. A., Wegmann, S., Maesako, M., Luo, C. C., Mylvaganam, R., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.784264 · Cited by 23
“Inheritance of the E4 allele is strongly associated with an increased risk for Alzheimer’s disease, and inheritance of the E2 allele is strongly associated with reduced risk of Alzheimer’s disease compared with the most common E3 allele (6).”
BackgroundThe proportion of Alzheimer’s disease attributable to apolipoprotein E
Williams, D. M., Heikkinen, S., Hiltunen, M. O., FinnGen, Davies, N. M., & Anderson, E. L. (2026) · npj Dementia · doi:10.1038/s44400-025-00045-9 · Cited by 35
“Codes are listed in Supplementary Tables 2 and 3.”
The Impact of the Human Genome Project on Complex Disease
Bailey, J. N. C., Pericak‐Vance, M. A., & Haines, J. L. (2014) · Genes · doi:10.3390/genes5030518 · Cited by 25
“The most recent efforts by the Alzheimer Disease Genetics Consortium (ADGC) and the International Genomics of Alzheimer’s Project (IGAP) have greatly increased the number of known loci associated with LOAD.”
BackgroundInfluentialSelf-citationEarly-life educational attainment, APOE ε4 alleles, and incident dementia risk in late life
Ma, H., Zhou, T., Li, X., Maraganore, D. M., Heianza, Y., & Qi, L. (2022) · GeroScience · doi:10.1007/s11357-022-00545-z · Cited by 27
“Participants with ε2/ε4 genotype were not included in the main analysis [20, 21], as such genotype have a combination of potentially protective and risk alleles (we performed a sensitivity analysis using the population including the APOE ε2/ε4 genotype).”
MethodDumuid, D., Mellow, M. L., Olds, T., Tregoweth, E., Greaves, D., Keage, H. A. D., & Smith, A. E. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220181 · Cited by 26
Wittrahm, R., Takalo, M., Kuulasmaa, T., Mäkinen, P. M., Mäkinen, P., Končarević, S., Fartzdinov, V., Selzer, S., Kokkola, T., Antikainen, L., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106140 · Cited by 22
“In contrast, the APOE2 allele protects against AD (29).”
Cerebrospinal fluid biomarkers of Alzheimer’s disease in cognitively healthy elderly
Glodzik, L. (2013) · Frontiers in bioscience · doi:10.2741/4170 · Cited by 29
Alzheimer disease: update on basic mechanisms.
Bi, X. (2010) · PubMed · Cited by 40
Chen, J., Shu, H., Wang, Z., Liu, D., Shi, Y., Xu, L., & Zhang, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.11289 · Cited by 23
“Furthermore, we found APOE the protective APOE ε2 allele appears to be against the disease [14, 15, 18, 19], whereas APOE ε4 allele accelerated the progression of early AD [13-15].”
Atomistic Insights into Structural Differences between E3 and E4 Isoforms of Apolipoprotein E
Ray, A., Ahalawat, N., & Mondal, J. (2017) · Biophysical Journal · doi:10.1016/j.bpj.2017.10.006 · Cited by 23
“ApoE4 also leads to reduced clearance of extracellular amyloid plaque deposits in the brain (14), increases neuronal degeneration (19), and reduces longevity (20).”
BackgroundApolipoprotein E is Present in Primary Localized Cutaneous Amyloidosis
Furumoto, H., Shimizu, T., Asagami, C., Muto, M., Takahashi, M., Hoshii, Y., Ishihara, T., & Nakamura, K. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00294.x · Cited by 24
Reiman, E. M., & Caselli, R. J. (1999) · Maturitas · doi:10.1016/s0378-5122(98)00110-8 · Cited by 43
Use of in Vivo Models to Study the Role of Cholesterol in the Etiology of Alzheimer's Disease
Burns, M. P., & Duff, K. (2003) · Neurochemical Research · doi:10.1023/a:1023294820218 · Cited by 26
Genetic Epidemiology of Alzheimer Disease
Mayeux, R. P. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200607001-00008 · Cited by 30
Apolipoprotein E genotype in schizophrenia
Joober, R., Rouleau, R. M., Fon, E. A., Lal, S., Palmour, R. M., Bloom, D., Labelle, A., & Benkelfat, C. (1996) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320670204 · Cited by 23
Apolipoprotein E, Cognitive Function, and Dementia in a General Population Aged 85 Years and Over
Juva, K., Verkkoniemi, A., Viramo, P., Polvikoski, T. M., Kainulainen, K., Kontula, K., & Sulkava, R. O. (2000) · International Psychogeriatrics · doi:10.1017/s1041610200006487 · Cited by 28
Diagnosis of Alzheimer's disease: defining genetic profiles (genotype vs phenotype)
Cacabelos, R. (1996) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1996.tb05875.x · Cited by 27
Parfenov, M. G., Nikolaeva, T. Y., Sudomoina, M. A., Федорова, С. А., Guekht, A. B., Gusev, E. I., & Favorova, O. O. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.01.068 · Cited by 24
MMSE Items Predict Cognitive Decline in Persons with Genetic Risk for Alzheimer's Disease
Ercoli, L. M., Siddarth, P., Dunkin, J. J., Bramen, J. E., & Small, G. W. (2003) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988703016002001 · Cited by 28
“Possession of the APOE4 allele confers substantial risk for AD in a dose-related fashion, while possession of the APOE-2 allele confers protection.(12,13) Possession of APOE-4 is predominately associated with verbal and visual (episodic) memory deficits,(14-16) but deficits in visuospatial ability and declines in verb…”
BackgroundSelf-citationMolecular Epidemiology of Alzheimer's Disease
Hyman, B. T., & Tanzi, R. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511093331910 · Cited by 27
den Heijer, T., van der Lijn, F., Ikram, M. A., Koudstaal, P. J., van der Lugt, A., Krestin, G. P., Vrooman, H. A., Hofman, A., Niessen, W. J., & Breteler, M. M. B. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.07.005 · Cited by 24
“This study found a lower rate of hippocampal decline in APOE 32 carriers compared with 3 carriers, which is consistent with the idea that the 32 allele may protect against AD [13].”
Clinical genetic strategies for early onset neurodegenerative diseases
Giau, V. V., Bagyinszky, E., An, S. S. A., & Kim, S. (2018) · Molecular & Cellular Toxicology · doi:10.1007/s13273-018-0015-3 · Cited by 25
Bratosiewicz‐Wąsik, J., Liberski, P. P., Pepłońska, B., Styczyńska, M., Smoleń‐Dzirba, J., Cycoń, M., & Wąsik, T. J. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.07.010 · Cited by 22
Nuytemans, K., Lipkin Vasquez, M., Wang, L., Van Booven, D., Griswold, A. J., Rajabli, F., Celis, K., Oron, O., Hofmann, N., Rolati, S., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12534 · Cited by 22
“(2) Higher enhancer activity (corresponding to higher expression) was found for the European alleles compared to the African alleles, supportingourpreviousobservations inADbrainsbetweenAfricanLAand European LA APOE ε4.”
ResultSelf-citationTriebswetter, C., Kiely, M., Khattar, N., Ferrucci, L., Resnick, S. M., Spencer, R. G. S., & Bouhrara, M. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.118988 · Cited by 22
“The apolipoprotein E ε4 (APOE ε4) allele has been linked to increased risk of Alzheimer’s disease (AD) development (6), while emerging evidence suggests a protective effect of the APOE ε2 allele (7-9).”
BackgroundApolipoprotein E Recognizes Alzheimer's Disease Associated 3‐O Sulfation of Heparan Sulfate
Mah, D., Zhu, Y., Su, G., Zhao, J., Canning, A., Gibson, J. M., Song, X., Stancanelli, E., Xu, Y., Zhang, F., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202212636 · Cited by 33
Genetic Animal Models of Cerebral Vasculopathies
Lee, J. H., Bacskai, B. J., & Ayata, C. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-394596-9.00002-0 · Cited by 24
“Among the three major alleles of ApoE,(128) e4 increases the risk of developing both late onset AD and sporadic CAA by enhancing the rate of amyloid fibril formation and deposition of Ab in vessels and senile plaques, whereas e2 promotes the rupture of amyloid-laden blood vessels, although it appears to reduce the ris…”
BackgroundNovel approaches to increase synaptic resilience as potential treatments for Alzheimer’s disease
Pham, A. Q., & Dore, K. (2023) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2022.03.032 · Cited by 21
Fan, J., Stukas, S., Wong, C., Chan, J., May, S., DeValle, N., Hirsch-Reinshagen, V., Wilkinson, A., Oda, M. N., & Wellington, C. L. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m014365 · Cited by 21
Kara, E., Marks, J. D., Roe, A. D., Commins, C., Fan, Z., Calvo-Rodriguez, M., Wegmann, S., Hudry, E., & Hyman, B. T. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001388 · Cited by 20
“It has been found that E4 increases the risk for development of Alzheimer’s disease (AD), whereas E2 has a protective role and E3 a neutral effect (1).”
BackgroundExploratory data from complete genomes of familial alzheimer disease age-at-onset outliers
Lalli, M. A., Garcia, G., Madrigal, L., Arcos-Burgos, M., Arcila, M. L., Kosik, K. S., & Lopera, F. (2012) · Human Mutation · doi:10.1002/humu.22167 · Cited by 19
“Seven genes contained both potential risk and protective variants, similar to APOE in which the ε4 allele is a risk factor and the ε2 allele is protective [Corder et al., 1993, 1994], potentially implicating these genes as molecular switches for the onset of the disease (Supp.”
BackgroundAssociations of APOE e2 genotype with cerebrovascular pathology: a postmortem study of 1275 brains
Goldberg, T. E., Huey, E. D., & Devanand, D. P. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323746 · Cited by 19
New insights into innate immunity in Alzheimer’s disease: From APOE protective variants to therapies
Chen, Y., & Holtzman, D. M. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.08.001 · Cited by 19
Golden, L. R., Siano, D. S., Stephens, I. O., MacLean, S. M., Saito, K., Nolt, G. L., Funnell, J. L., Pallerla, A. V., Lee, S., Smith, C., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02094-y · Cited by 31
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Yale University (US)
- Massachusetts General Hospital (US)
- Indiana University School of Medicine (US)
- University of California, Los Angeles (US)
- Venue
- Nature Genetics
- Published
- 1994-06
- Volume
- 7
- Issue
- 2
- Pages
- 180-184
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2090271811
- Cited by
- 1,920
- References
- 41
- Citations by year
- 2026: 45 · 2025: 77 · 2024: 78 · 2023: 59 · 2022: 66 · 2021: 76 · 2020: 76 · 2019: 58 · 2018: 62 · 2017: 58 · 2016: 75 · 2015: 55 · 2014: 63 · 2013: 68 · 2012: 66
- FWCI
- 54.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (NIA AG05128, U24AG021886)
- National Institute of Neurological Disorders and Stroke (P01NS026630, NINDS NS26630, NINDS NS531153)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, late-onset Alzheimer's disease, familial Alzheimer's disease, gene dosage, protective effect, sporadic Alzheimer's disease, genetic risk factors, APOE genotype
- MeSH terms
- Aged, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Humans, Male, Middle Aged, Risk Factors, Odds Ratio, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.